The FDA has determined that the risk evaluation and mitigation strategy for erythropoiesis-stimulating agents, specifically relating to the use of Epogen/Procrit (epoetin alfa, Amgen Inc. and Johnson & Johnson) and Aranesp (darbepoetin alfa, Amgen Inc.) for treating anemia due to associated myelosuppressive chemotherapy, is no longer necessary to ensure the benefits of those drugs outweigh their risk of shortened overall survival and/or increased risk of tumor progression or recurrence in patients with cancer.